Background. The probable impact of growth hormone (GH) as a heart failure (HF) treatment strategy is still less investigated. Therefore, we aimed to evaluate the relation of 3-month GH prescription on left ventricular ejection fraction (LVEF), interventricular septum (IVS), posterior left ventricle (LV) thickness, end systolic and end diastolic diameters (ESD and EDD), and pulmonary arterial pressure (PAP) among Iranian individuals suffering from HF due to MI attack. Methods. A total of 16 clinically stable participants with HF diagnosis and % were selected for enrollment in this pilot randomized double-blinded study. They were randomly assigned equally to groups received 5 IU subcutaneous GH or placebo. Injections were done every other day for a total of 3-month duration. After termination of intervention and nine months afterwards, cardiac outcomes were assessed. Results. Baseline and 12-month posttrial participants’ characteristics were similar. LVEF was increased significantly by three months started from baseline in individuals receiving GH (% to %, ). During the next 9 months of follow-up concurrent with cessation of injections, LVEF was declined (% to %, ). LVEF and ESD were remarkably higher and lower in GH group compared with controls by the end date of injections (% vs. %, and  mm vs.  mm, , respectively). No other considerable association was found in terms of other predefined variables in neither GH nor placebo groups. Conclusions. GH administration in HF patients was associated with increased LVEF function. Several randomized clinical trials are necessary proving this relation. This trial is registered with IRCT201704083035N1.

中文翻译：

---

心肌梗死 4 周后心力衰竭患者 3 个月生长激素给药和 12 个月随访时间的影响：一项随机双盲临床试验

背景。生长激素 (GH) 作为心力衰竭 (HF) 治疗策略的可能影响仍然较少研究。因此，我们旨在评估 3 个月 GH 处方与左心室射血分数 (LVEF)、室间隔 (IVS)、左心室后部 (LV) 厚度、收缩末期和舒张末期直径 (ESD 和 EDD) 的关系，以及因心肌梗死发作而患有心力衰竭的伊朗人的肺动脉压 (PAP)。方法。共有 16 名临床稳定的 HF 诊断参与者和% 被选入这项试验性随机双盲研究。他们被随机分配到接受 5 IU 皮下 GH 或安慰剂的组。每隔一天注射一次，共持续 3 个月。干预终止后和九个月后，评估心脏结果。结果。基线和 12 个月试验后参与者的特征相似。接受 GH 的个体的 LVEF 从基线开始在三个月内显着增加（％ 到%,）。在随后 9 个月的随访期间，同时停止注射，LVEF 下降（％ 到%,）。到注射结束日期，与对照组相比，GH 组的 LVEF 和 ESD 显着升高和降低（% 对比%,和 毫米对比 毫米，，分别）。在 GH 组和安慰剂组中均未发现其他预定义变量的其他显着关联。结论。HF 患者的 GH 给药与 LVEF 功能增加有关。有必要进行几项随机临床试验来证明这种关系。该试验已在 IRCT201704083035N1 注册。